---
title: "Linzess (linaclotide) in irritable bowel syndrome with constipation: Safety questions"
description: "Safety questions on Linzess (linaclotide) in irritable bowel syndrome with constipation, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects. Questions: What are the most common side effects of Linzess for IBS-C in adults? How common is diarrhea with Linzess in adults with IBS-C? How many adults with IBS-C stopped Linzess because of side effects? In long-term Linzess IBS-C trials, how often did side effects lead to dose reduction? 2 further questions follow. 6 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Linzess (linaclotide) in irritable bowel syndrome with constipation: Safety questions

Manufacturer: AbbVie, Inc.; Ironwood Pharmaceuticals, Inc.  
Prescribing information: [Linzess](https://www.rxabbvie.com/pdf/linzess_pi.pdf)

Safety questions that apply to every indication of Linzess are on [Linzess (linaclotide), all indications: Safety](https://www.evicenter.com/medical-information/linzess/safety).

## Side effects

<a id="linzess-side-effects"></a>

### What are the most common side effects of Linzess for IBS-C in adults?

Applies to: Irritable bowel syndrome with constipation (IBS-C) in adults

> “LINZESS was evaluated in placebo-controlled trials lasting up to 26 weeks involving more than 2,200 adults with IBS-C”

Source: [LINZESS: LINZESS® (linaclotide) Safety Profile Among IBS-C Patients | For HCPs, captured 2026-11-14](https://www.linzesshcp.com/linzess-ibs-c-safety#:~:text=LINZESS%20was%20evaluated%20in%20placebo%2Dcontrolled,than%202%2C200%20adults%20with%20IBS%2DC)

> “The data described below reflect exposure to LINZESS in the two placebo-controlled clinical 
> trials involving 1605 adult patients with IBS-C (Trials 1 and 2) [see Clinical Studies (14.1)]. 
> Patients were randomized to receive placebo or 290 mcg LINZESS once daily on an empty 
> stomach for up to 26 weeks. Table 1 provides the incidence of adverse reactions reported in at 
> least 2% of IBS-C patients in the LINZESS treatment group and at an incidence that was 
> greater than in the placebo group.  
>
> Table 1:  
> Most Common Adverse Reactions<sup>a</sup> in Two Placebo-Controlled Trials (1 and 
> 2) in Adult Patients with IBS-C 
> Adverse Reactions 
>
> LINZESS 
> 290 mcg 
> [N=807] 
> % 
>
> Placebo 
> [N=798] 
> % 
> Gastrointestinal 
> Diarrhea 
> Abdominal pain<sup>b</sup> 
> Flatulence 
> Abdominal distension 
>
> 20 
> 7 
> 4 
> 2 
>
> 3 
> 5 
> 2 
> 1 
> Infections and Infestations 
>   Viral Gastroenteritis  
>
> 3 
>
> 1 
> Nervous System Disorders 
> Headache 
>
> 4 
>
> 3 
> a: Reported in at least 2% of LINZESS-treated patients and at an incidence greater than placebo  
> b: “Abdominal pain” term includes abdominal pain, upper abdominal pain, and lower abdominal pain.  
>
> Adverse reactions in an additional placebo-controlled trial in 614 IBS-C patients randomized to 
> placebo or LINZESS 290 mcg once daily on an empty stomach for 12 weeks (Trial 6) were 
> similar to those in Table 1.”

Source: [LINZESS: Prescribing information, page 5, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=5)

Note: Table 1 columns are LINZESS 290 mcg (N=807) and placebo (N=798), in that order (% of patients). The figure of more than 2,200 adults on the safety page includes placebo-treated patients and Trial 6 (the label's geriatric use section counts 2219 IBS-C patients in Trials 1, 2, and 6); Table 1 is from Trials 1 and 2.

<a id="linzess-diarrhea"></a>

### How common is diarrhea with Linzess in adults with IBS-C?

Applies to: Irritable bowel syndrome with constipation (IBS-C) in adults

> “Diarrhea was the most commonly reported adverse reaction of the LINZESS-treated patients 
> in the pooled IBS-C pivotal placebo-controlled trials. In these trials, 20% of LINZESS-treated 
> patients reported diarrhea compared to 3% of placebo-treated patients. Severe diarrhea was”

Source: [LINZESS: Prescribing information, page 5, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=5)

> “reported in 2% of the LINZESS-treated patients versus less than 1% of the placebo-treated 
> patients, and 5% of LINZESS-treated patients discontinued due to diarrhea vs less than 1% of 
> placebo-treated patients. The majority of reported cases of diarrhea started within the first 2 
> weeks of LINZESS treatment [see Warnings and Precautions (5.2)].”

Source: [LINZESS: Prescribing information, page 6, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=6)

<a id="linzess-discontinuation"></a>

### How many adults with IBS-C stopped Linzess because of side effects?

Applies to: Irritable bowel syndrome with constipation (IBS-C) in adults

> “In placebo-controlled trials in patients with IBS-C, 9% of patients treated with LINZESS and 3% 
> of patients treated with placebo discontinued prematurely due to adverse reactions. In the 
> LINZESS-treatment group, the most common reasons for discontinuation due to adverse 
> reactions were diarrhea (5%) and abdominal pain (1%). In comparison, less than 1% of 
> patients in the placebo group withdrew due to diarrhea or abdominal pain.”

Source: [LINZESS: Prescribing information, page 6, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=6)

<a id="linzess-long-term-dose-reduction"></a>

### In long-term Linzess IBS-C trials, how often did side effects lead to dose reduction?

Applies to: Irritable bowel syndrome with constipation (IBS-C) in adults

> “In the open-label, long-term trials, 2147 patients with IBS-C received 290 mcg of LINZESS 
> daily for up to 18 months. In these trials, 29% of patients had their dose reduced or suspended 
> secondary to adverse reactions, the majority of which were diarrhea or other GI adverse 
> reactions.”

Source: [LINZESS: Prescribing information, page 6, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=6)

<a id="linzess-less-common-side-effects"></a>

### What less common side effects were reported with Linzess in adults with IBS-C?

Applies to: Irritable bowel syndrome with constipation (IBS-C) in adults

> “Defecation urgency, fecal incontinence, vomiting, and gastroesophageal reflux disease were 
> reported in <2% of patients in the LINZESS-treatment group and at an incidence greater than 
> in the placebo treatment group.”

Source: [LINZESS: Prescribing information, page 6, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=6)

<a id="linzess-pediatric-side-effects"></a>

### What are the side effects of Linzess in children with IBS-C?

Applies to: Irritable bowel syndrome with constipation (IBS-C) in pediatric patients 7 years of age and older

> “The safety of LINZESS 145 mcg once daily was evaluated in 55 pediatric patients 7 to 17 
> years of age with IBS-C in a 12-week double-blind, parallel-group clinical trial (Trial 8) [see 
> Clinical Studies (14.2)].  
>
> The safety profile in pediatric patients treated with LINZESS was similar to the safety profile 
> from trials in adults with IBS-C and CIC and in pediatric patients with FC. Diarrhea was the 
> most common adverse reaction reported in 7% of 145 mcg LINZESS-treated pediatric patients. 
> Most reported cases of diarrhea started within the first 2 weeks of LINZESS treatment [see 
> Warnings and Precautions (5.2)].”

Source: [LINZESS: Prescribing information, page 6, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=6)

> “• In a double-blind trial of patients 7 to 17 years of age with IBS-C, diarrhea was reported 
> in 7% and 8% of patients treated with LINZESS 145 mcg and 290 mcg once daily, 
> respectively. One severe case of diarrhea was reported in the IBS-C trial at a dosage 
> higher than the recommended LINZESS 145 mcg once daily dosage for IBS-C.”

Source: [LINZESS: Prescribing information, page 4, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=4)

Note: 290 mcg is higher than the recommended pediatric IBS-C dosage of 145 mcg once daily (see the IBS-C dose question).

## Related pages
- [Medical information: Linzess (linaclotide): Irritable bowel syndrome with constipation](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation)
- [Clinical trials](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation/guidelines)
